Alicyclic Ring Containing Patents (Class 514/690)
-
Publication number: 20140249160Abstract: Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity.Type: ApplicationFiled: February 6, 2014Publication date: September 4, 2014Applicant: Edison Pharmaceuticals, Inc.Inventor: Guy M. MILLER
-
Publication number: 20140249234Abstract: The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to restore the stratum granulosum and stratum corneum and treat a dermatological disease, such as, for instance atopic dermatitis. More specifically it provides terpenes and terpenoids such as monoterpenoids, sesquiterpenes and norisoprenoids as ingredients that work to restore and thicken the stratum granulosum and stratum corneum and treat a dermatological disease. Terpenes and terpenoid compounds support the cell proliferation, cell differentiation, growth of skin, skin tissue and keratinocytes by upregulating genes for loricrin filaggrin, caspase 14, hornerin and other late cornified envelope components and vascular endothelial growth factor (VEGF) and downregulation of matrix metalloproteinases. Both terpenes and terpenoids may be applied topically or orally at oral or topical concentrations from about 0.Type: ApplicationFiled: June 6, 2012Publication date: September 4, 2014Inventors: Frederic J. Burns, Ivica Labuda
-
Publication number: 20140248249Abstract: A method of treatment is disclosed, comprising administering a composition of Cyclodextrin and one or more of a natural molecule or fragment thereof in at least one carrier to a patient in need of treatment, wherein the natural molecule is non-acetylated, non-Esterified, and non-fatty acid attached.Type: ApplicationFiled: May 12, 2014Publication date: September 4, 2014Inventors: Nayan Patel, Chinh Tran
-
Publication number: 20140242055Abstract: Provided herein are compositions and methods for preparing foods and beverages that contain additives, such as nutraceuticals, pharmaceuticals, and supplements, such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Inventor: Philip J. Bromley
-
Patent number: 8815306Abstract: Methods and compositions that can be used to promote bone and joint health through amelioration, stabilization and repair of damage associated with various pathophysiological conditions are disclosed.Type: GrantFiled: March 14, 2008Date of Patent: August 26, 2014Assignee: Metaproteomics, LLCInventors: Matthew L. Tripp, Veera Konda, Anu Desai, Amy J. Hall, Jeffrey S. Bland
-
Patent number: 8815300Abstract: The formulations of the present disclosure alter the perception of pain, especially as experienced by subjects reporting the characteristic features associated with the syndrome known as fibromyalgia. The present disclosure encompasses formulations for the relief of symptoms associated with neuropathy pain, where the formulations comprise orthophosphoric acid, a vegetable oil comprising an esterified mono-unsaturated fatty acid, and folic acid. The formulations can further comprise magnesium citrate, magnesium aspartate, malic acid, L-carnitine, alpha-ketoglutaric acid, co-enzyme Q10, glycerol, inositol, and cholinebitartrate, optionally Q10, and riboflavin to provide a yellow color to the formulation. Another aspect of the disclosure are methods for alleviating neuropathy related pain in subject animal or human, comprising: providing to a subject an effective dose of a formulation comprising orthophosphoric acid, a mono-unsaturated fat, folic acid, and water.Type: GrantFiled: August 28, 2009Date of Patent: August 26, 2014Assignee: Coastal Biologic SolutionsInventor: Jeffrey Comanor
-
Publication number: 20140227242Abstract: Provided are compositions and methods for producing stable foods and beverages that contain high concentrations of additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols and carotenoids; oil soluble vitamins; alpha lipoic acid; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.Type: ApplicationFiled: April 15, 2014Publication date: August 14, 2014Inventors: Philip J. Bromley, Chetan S. Rao
-
Patent number: 8796326Abstract: A fire ant killer chemical composition (the “FAK Composition”) for effective killing of fire ants where the FAK Composition utilizes a minimal amount of active ingredients thereby significantly reducing safety concerns with respect to the use of said active ingredients, the FAK composition having a dish detergent composition and an insecticide composition.Type: GrantFiled: January 4, 2012Date of Patent: August 5, 2014Inventor: Harold V. Hutchins
-
Publication number: 20140213558Abstract: Embodiments of the invention relate generally to the treatment of inflammatory diseases and disorders and, more particularly, to the treatment of symptoms of inflammatory diseases and disorders using thymoquinone (TQ) alone or in combination with other compounds, including eicosapentaenoic acid (EPA). In one embodiment, the invention provides a pharmaceutical composition suitable for the treatment of at least one symptom of an inflammatory disease or disorder, comprising: an effective amount of thymoquinone; and at least one physiologically-acceptable carrier, wherein an effective amount of thymoquinone is an amount capable of reducing or preventing the at least one symptom of the inflammatory disease or disorder.Type: ApplicationFiled: August 17, 2012Publication date: July 31, 2014Applicant: CREDE OILS (PTY) LTDInventor: Philipp Crede
-
Publication number: 20140212402Abstract: The present invention provides a stabilization method, a preservation method and the like method of reduced coenzyme Q10, which is useful as functional nutritive foods, specific health foods and the like. Furthermore, the present invention provides a method for efficiently obtaining reduced coenzyme Q10 of high quality and by a method suitable for a commercial production. It is possible to handle and stably preserve reduced coenzyme Q10 under a condition that oxidation by a molecular oxygen is inhibited by contacting reduced coenzyme Q10 with, an ascorbic acid and citric acid or a related compound thereof, and thus a stabilized composition is obtained. Moreover, reduced coenzyme Q10 is converted into a crystalline state in such a condition that the formation of oxidized coenzyme Q10 as a byproduct is minimized by crystallizing reduced coenzyme Q10 in the presence of ascorbic acid or a related compound thereof etc., and thus a reduced coenzyme Q10 crystal of high quality is produced.Type: ApplicationFiled: March 5, 2014Publication date: July 31, 2014Applicant: Kaneka CorporationInventors: Takahiro Ueda, Tadao Ono, Mitsutoshi Moro, Shiro Kitamura, Yasuyoshi Ueda
-
Publication number: 20140206772Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD—not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.Type: ApplicationFiled: January 14, 2014Publication date: July 24, 2014Inventors: Guy M. Miller, Viktoria Kheifets
-
Publication number: 20140200226Abstract: Novel compositions and methods for the treatment and prevention of malaria are disclosed herein.Type: ApplicationFiled: December 12, 2013Publication date: July 17, 2014Applicants: Florida Atlantic University, University of Central Florida Research Foundation, Inc.Inventors: Debopam Chakrabarti, Amy Wright
-
Patent number: 8778410Abstract: The present invention provides an oral or enteral composition incorporating not only BCAA but other nutrients to be conducive to comprehensive recovery from fatigue, and improvement in total physical condition. The oral or enteral composition is formulated as a composite of a branched-chain amino acid, coenzyme Q10, L-carnitine, a citric acid, and zinc.Type: GrantFiled: February 19, 2009Date of Patent: July 15, 2014Assignees: Earnest Medicine Co., Ltd., Otsuka Pharmaceutical Factory, Inc.Inventors: Takashi Higashiguchi, Takako Hatakeyama
-
Patent number: 8771652Abstract: The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to rejuvenate the skin and increase the protective layer against irradiation by ultraviolet radiation (UVR). More specifically it provides terpenes and terpenoids as ingredients that work as persistent UVR blockers. Terpenes and terpenoid compounds support the growth of skin, skin tissue and keratinocytes and additional UVR-blocking by reason of increased stratum corneum thickness and loricrin content. Both terpenes and terpenoids may be applied topically or orally at oral or topical concentrations from about 6 mg to about 600 mg per kilogram of body weight per day effective to stimulate growth of the skin layer and prevent damage from ultraviolet radiation (UVR).Type: GrantFiled: September 17, 2010Date of Patent: July 8, 2014Assignees: New York University, Biokeys for Flavors, LLCInventors: Ivica Labuda, Fredric Jay Burns
-
Patent number: 8772349Abstract: Cannabinoid quinone derivatives. The present invention refers to cannabinoid quinone derivatives to be used as medicaments, particularly as PPAR gamma (PPARg) agonists for treating diseases which etiology is based on an impaired PPARg function as transcription factor i.e. PPARg-related diseases.Type: GrantFiled: March 26, 2010Date of Patent: July 8, 2014Assignee: Vivacell Biotechnology Espana, S.L.Inventors: Eduardo Muñoz Blanco, Giovanni Appendino, María Luz Bellido Cabello De Alba
-
Patent number: 8772348Abstract: The present invention provides a novel insecticide formulation that not only demonstrates strong insecticidal and residual activity against a variety of insects, but also exhibits low mammalian toxicity. In certain embodiments, the present invention relates to the use of pesticidal compounds selected from beta damascone, CYCLEMONE A™, melafleur, and derivatives thereof for killing arthropod pests including, but not limited to, mosquitoes and flies. Specifically exemplified herein is the use of the compounds of the present invention to control three mosquitoes (Aedes aegypti, Ae. albopictus, and Anopheles quadrimaculatus), the house fly (Musca domestica), the stable fly (Stomoxys calcitrans) and the sand fly (Lutzomyia shannoni).Type: GrantFiled: December 3, 2010Date of Patent: July 8, 2014Assignee: University of Florida Research Foundation, Inc.Inventors: Phillip Edward Kaufman, Rajinder Singh Mann, Jerry Frank Butler
-
Method for Treating Metabolic Syndrome and Diabetes Using Quercetin and Bauhinia fortificata Extract
Publication number: 20140186321Abstract: This invention relates to a method of treating metabolic syndrome and diabetes using a composition containing quercetin, vitamin B3, vitamin C, and a Bauhinia fortificata extract.Type: ApplicationFiled: December 28, 2012Publication date: July 3, 2014Inventor: Thomas Christian Lines -
Publication number: 20140179801Abstract: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3 -dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6, 10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of lymphoma cells and be used as a pharmaceutical composition to inhibit the lymphoma tumor growth.Type: ApplicationFiled: March 3, 2014Publication date: June 26, 2014Applicant: Golden Biotechnology CorporationInventors: Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
-
Publication number: 20140179800Abstract: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of bladder cancer cells and be used as a pharmaceutical composition to inhibit the bladder tumor growth.Type: ApplicationFiled: February 28, 2014Publication date: June 26, 2014Applicant: Golden Biotechnology CorporationInventors: Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
-
Patent number: 8758743Abstract: A coenzyme Q10-containing composition comprising a coenzyme Q10 and a hydrophilic fatty acid ester of a polyhydric alcohol; a coenzyme Q10-containing composition comprising a coenzyme Q10, a lipophilic fatty acid ester of a polyhydric alcohol and a hydrophilic fatty acid ester of a polyhydric alcohol; and a food or beverage comprising the coenzyme Q10-containing composition as defined above.Type: GrantFiled: January 15, 2004Date of Patent: June 24, 2014Assignee: Taiyo Kagaku Co., Ltd.Inventors: Rumi Yamaguchi, Hiroaki Yamaguchi, Hironobu Nanbu, Lekh Raj Juneja, Nagahiro Yamazaki
-
Publication number: 20140170085Abstract: A process for producing a cosmetic preparation wherein a cosmetic base, admixed with one or more cosmetic partial preparations or active ingredient concentrates, is mounted, in the package intended for the end user, in a dually asymmetric centrifuge, and is centrifuged in such a way that the cosmetic part preparations or active ingredient concentrates are distributed uniformly in the cosmetic base.Type: ApplicationFiled: January 18, 2013Publication date: June 19, 2014Applicant: Beiersdorf AGInventors: Ann-Sophie PETERS, Heiner Gers-Barlag
-
Publication number: 20140147496Abstract: A new composition and method are described for male fertility therapy. In one particular embodiment, the composition comprises Lepidium meyenii, carnitine and Coenzyme Q10. When it is administered to males as fertility therapy following the recommended therapeutic regimen, enhanced sperm count, sperm quality, and sperm motility results.Type: ApplicationFiled: January 28, 2014Publication date: May 29, 2014Applicant: FAIRHAVEN HEALTH, LLCInventors: Kelly Andrews, Amos N. Grunebaum
-
Publication number: 20140140974Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.Type: ApplicationFiled: January 27, 2014Publication date: May 22, 2014Applicant: Soft Gel Technologies, Inc.Inventor: Michael Fantuzzi
-
Publication number: 20140135402Abstract: The present invention relates to compounds of Formula (I), wherein one R group is a hydrogen atom and the other is a hydrogen atom or a C1-3 alkyl group; and each carbon-carbon double bond of said compound, independently from each other, can be in a configuration Z or E or a mixture thereof; which are useful perfuming ingredients.Type: ApplicationFiled: June 18, 2012Publication date: May 15, 2014Applicant: FIRMENICH SAInventor: Peter Fankhauser
-
Patent number: 8716486Abstract: Methods of treating or suppressing oxidative stress disorders including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-heterocyclylaminoalkyl-(p-quinone) derivatives.Type: GrantFiled: June 23, 2009Date of Patent: May 6, 2014Assignee: Edison Pharmaceuticals, Inc.Inventors: Andrew W. Hinman, Orion D. Jankowski, Kieron E. Wesson
-
Publication number: 20140120073Abstract: With respect to reduced coenzyme Q10, there has been no report about the presence of crystal polymorphism, and it has been considered that a conventionally obtained crystal form is only one form. The present invention relates to a reduced coenzyme Q10 crystal having an endothermic peak indicating melting at 54±2° C. during temperature rise at a rate of 5° C./min by differential scanning calorimetry (DSC), and/or to a reduced coenzyme Q10 crystal showing characteristic peaks at diffraction angles (2?±0.2°) of 11.5°, 18.2°, 19.3°, 22.3°, 23.0° and 33.3° by powder X-ray (Cu—K?) diffraction. The crystal form is a novel reduced coenzyme Q10 crystal which has a higher melting point and a lower solubility in a solvent, and is more excellent in stability than the conventionally known reduced coenzyme Q10 crystal.Type: ApplicationFiled: June 21, 2012Publication date: May 1, 2014Applicant: KANEKA CORPORATIONInventors: Hideo Kawachi, Shiro Kitamura, Yasuyoshi Ueda
-
Patent number: 8703195Abstract: Disclosed is a method in which poloxamer, a resin, and/or a tocopherol is/are fused, and the material that is to be treated is intimately dispersed with said melt. After being introduced into the melt, the material that is to be treated is coated with water to prevent hardening, and the spontaneously forming gel is homogenized. The obtained product is composed of a transparent gel that is based on at least one poloxamer, a resin or a tocopherol, and an active substance which is solubilized, dispersed, and stabilized therein and whose consistency ranges from solid, semisolid, i.e. aspic-like, to liquid. The micelles of said solubilized matter remain stable even when the same is diluted well below the CMC of poloxamer.Type: GrantFiled: March 9, 2007Date of Patent: April 22, 2014Assignee: Biorem AGInventor: Hanspeter Strobel
-
Publication number: 20140105877Abstract: The present invention is directed to a composition of matter, in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively. The composition of matter reduces the risk of neuropathy, neurodegenerative diseases including late-onset Alzheimer's disease, and cancer, in particular of pancreatic, esophageal, oropharyngolaryngeal, liver, colorectal, lung and/or breast cancer, in particular the drug and/or alcohol induced risk of said diseases. In this respect, the present invention is also directed to a composition of matter, in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively, which supports and/or moderates the alcohol degradation process within the human body.Type: ApplicationFiled: October 21, 2013Publication date: April 17, 2014Applicant: Tima FoundationInventor: Markus Graf von MATUSCHKA-GREIFFENCLAU
-
Publication number: 20140105879Abstract: The invention relates to a functional flour-based food composition, in particular baked products, and a method for the preparation thereof. Specific substances of vegetable origin principally containing policosanols, isoflavones and vegetable statins are added to the flour, or to the dough for preparing the aforesaid baked products. Further components can be added to the preparation in order to enhance the effectiveness and sensory qualities thereof. The functional food composition of the invention favours the re-balancing of cholesterol and triglyceride values.Type: ApplicationFiled: April 5, 2012Publication date: April 17, 2014Inventor: Guglielmo Buonamici
-
Publication number: 20140093489Abstract: A nutritional or dietary supplement composition that strengthens and promotes a general eye health benefit for aging adults, including retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts.Type: ApplicationFiled: September 30, 2013Publication date: April 3, 2014Inventor: Robert DiSilvestro
-
Patent number: 8685391Abstract: Dermatological and cosmetic compositions and methods are provided to reduce the appearance of biological and/or environmentally-caused aging.Type: GrantFiled: September 6, 2012Date of Patent: April 1, 2014Assignee: Jan Marini Skin Research, Inc.Inventor: Jan Marini
-
Publication number: 20140086894Abstract: Compositions and their use in the treatment or prevention of hyperglycemia and related diseases or disorders are disclosed.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: TIMA FOUNDATIONInventors: Markus MATUSCHKA-GREIFFENCLAU, Haruhiko INUFUSA
-
Publication number: 20140079836Abstract: Described herein are the results of comprehensive genetic expression and other molecular analysis of the effect of antioxidants on biological systems, including specifically different human cells. Based on these analyses, methods and compositions are described for modifying or influencing the lifespan of cells, tissues, organs, and organisms. In various embodiments, there are provided methods for modulating the activity of the gene maintenance process in order to influence the length and/or structural integrity of the telomere in living cells, as well as methods for modulating the rate/efficiency of the cellular respiration provided by the mitochondria, mitochondrial biogenesis, and maintenance of the mitochondrial membrane potential.Type: ApplicationFiled: November 19, 2013Publication date: March 20, 2014Inventor: David H. McDaniel
-
Patent number: 8669292Abstract: The invention provides compositions and formulations comprising catechol and/or acetogenins and various combinations thereof; including various combinations with other ingredients including botanical preparations containing acetogenin, an extract of green tea or a therapeutically active flavanoid contained in green tea; and one or more quinones. The invention includes a pharmaceutical composition including a salt of rhodizonic acid, an OH anion-generating base, a non-toxic acid, a quinone, a salt-containing sulfite, catechol and optionally, an acetogenin and an extract of green tea. The compositions and formulations demonstrate positive effects against a broad variety of cancer, autoimmune diseases, viruses and provides antioxidant protection against peroxyl hydrophilic, peroxyl lipophilic, hydroxyl, peroxynitrite and super oxide radicals. The compositions and formulations can be used for nutritional and nutraceutical uses, and used as dietary supplements.Type: GrantFiled: April 17, 2009Date of Patent: March 11, 2014Assignee: Orion Therapeutics, LLCInventor: Jerome Godin
-
Publication number: 20140066520Abstract: Disclosed is a pharmaceutical composition including a therapeutic quantity of a COX-2 inhibitor having an IC50-WHMA COX-2/COX-1 ratio ranging from about 0.23 to about 3.33 with reduced gastrointestinal and cardiovascular toxicity. Also disclosed are methods for treating osteoarthritis, rheumatoid arthritis or acute pain with less side-effects and faster onset of action utilizing the disclosed pharmaceutical composition.Type: ApplicationFiled: November 5, 2013Publication date: March 6, 2014Applicant: METAPROTEOMICS, LLCInventor: Eric Hauser KUHRTS
-
Publication number: 20140056863Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid eicosapentaenoic acid. It may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, ?-ketoglutarate, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.Type: ApplicationFiled: April 18, 2012Publication date: February 27, 2014Applicant: Nestec S.A.Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
-
Publication number: 20140056862Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and ?-ketoglutarate. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.Type: ApplicationFiled: April 18, 2012Publication date: February 27, 2014Applicant: Nestec S.A.Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
-
Patent number: 8653144Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.Type: GrantFiled: October 12, 2012Date of Patent: February 18, 2014Assignee: Edison Pharmaceuticals, Inc.Inventors: Guy M. Miller, Viktoria Kheifets
-
Publication number: 20140044693Abstract: Some aspects of the invention provide for a method of treating Wet and/or Dry Age-related Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, cataracts, and/or Stargardt Disease using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.Type: ApplicationFiled: April 24, 2012Publication date: February 13, 2014Applicant: RETROTOPE, INC.Inventor: Mikhail S. Shchepnov
-
Publication number: 20140044691Abstract: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach.Type: ApplicationFiled: October 14, 2013Publication date: February 13, 2014Inventors: Janmarie Hornack, Lawrence E. Dorman
-
Patent number: 8647651Abstract: Antimicrobial mixtures comprising or consisting of: one or more branched or unbranched alkanediols having 6-12 carbon atoms, one, two or more compounds chosen from the group consisting of the tropolones of the formula (I) wherein the substituents R1, R2, R3, R4 and R5 independently of one another have the following meaning: H; linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; OH; OR6, wherein R6 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; COOH; COOR7, wherein R7 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; NO2; NH2; F, Cl, Br, I; are described.Type: GrantFiled: July 27, 2006Date of Patent: February 11, 2014Assignee: Symrise AGInventors: Gerhard Schmaus, Sabine Lange, Ravikumar Pillai, William Johncock
-
Publication number: 20140037743Abstract: The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa.Type: ApplicationFiled: October 11, 2013Publication date: February 6, 2014Applicant: DelivRx, Inc.Inventor: Daniel R. DeBrouse
-
Publication number: 20140039065Abstract: The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.Type: ApplicationFiled: April 9, 2013Publication date: February 6, 2014Applicant: Edison Pharmaceuticals, Inc.Inventor: Edison Pharmaceuticals, Inc.
-
Publication number: 20140031433Abstract: A formulation, comprising an ophthalmically effective amount of one or more tocotrienol quinones, particularly of alpha-tocotrienol quinone is disclosed. Use of a formulation comprising one or more tocotrienol quinones for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also discussed. A method of treating or controlling the ocular symptoms associated with neurodegenerative diseases or trauma with a formulation comprising one or more tocotrienol quinones is also discussed. A method of treating or controlling the ocular symptoms associated with mitochondrial myopathies with a formulation comprising one or more tocotrienol quinones is also discussed.Type: ApplicationFiled: January 10, 2013Publication date: January 30, 2014Applicant: EDISON PHARMACEUTICALS, INC.Inventor: EDISON PHARMACEUTICALS, INC.
-
Publication number: 20140031321Abstract: The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole, and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof.Type: ApplicationFiled: January 14, 2013Publication date: January 30, 2014Applicant: CELTAXSYS, INC.Inventor: Erica Brook Goodhew
-
Publication number: 20140023627Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animcal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.Type: ApplicationFiled: September 19, 2013Publication date: January 23, 2014Applicant: University of MiamiInventors: Sung L. HSIA, Niven Rajin Narain, Jie Li, Kathryn J. Russell, Karrune V. Woan, Indushekhar Persaud
-
Publication number: 20140017219Abstract: A composition for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death comprise a fatty acid component enriched for one or more activated fatty acids and a nutraceutically acceptable excipient. A method for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death includes administering a fatty acid component enriched for one or more activated fatty acids.Type: ApplicationFiled: September 19, 2013Publication date: January 16, 2014Applicant: Nitromega Corp.Inventor: Raymond A. Miller
-
Patent number: 8609729Abstract: Disclosed is a method for treating macular degeneration in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2? isopropyl ester.Type: GrantFiled: April 12, 2010Date of Patent: December 17, 2013Assignee: Sucampo AGInventors: Ryuji Ueno, John Cuppoletti
-
Publication number: 20130330408Abstract: The present invention generally relates to improvements in the bioavailability and/or solubility of coenzyme Q10. For example, the present invention relates to methods for preparing particulate compositions including coenzyme Q10 that generally comprise dispersing and/or dissolving the coenzyme Q10 throughout a suitable solvent, and combining the coenzyme Q10 and an encapsulating (e.g., microencapsulating) agent. The present invention also generally relates to particulate compositions comprising coenzyme Q10 that exhibit improved bioavailability and/or solubility as compared to previous coenzyme Q10 products.Type: ApplicationFiled: March 16, 2012Publication date: December 12, 2013Applicant: PARTICLE DYNAMICS INTERNATIONAL, LLCInventor: Irwin C. Jacobs
-
Publication number: 20130330405Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.Type: ApplicationFiled: August 13, 2013Publication date: December 12, 2013Applicant: Soft Gel Technologies, Inc.Inventor: Michael Fantuzzi